Trials / Terminated
TerminatedNCT04644315
A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
A Phase II, Open-Label, Single Arm Decentralized Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
Conditions
- Neoplasms
- Colorectal Neoplasms
- Melanoma
- Pancreatic Neoplasms
- Sarcoma
- Ovarian Neoplasms
- Brain Neoplasms
- Thyroid Neoplasms
- Neuroendocrine Tumors
- Cholangiocarcinoma
- Salivary Gland Neoplasms
- Head and Neck Neoplasms
- Thyroid Cancer, Papillary
- Lymphoma, Large-Cell, Anaplastic
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Respiratory Tract Diseases
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Intestinal Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Central Nervous System
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alectinib | Participants will receive 600 mg oral alectinib BID until disease progression, unacceptable toxicity, withdrawal from treatment, or death. |
Timeline
- Start date
- 2021-05-24
- Primary completion
- 2022-05-16
- Completion
- 2022-05-16
- First posted
- 2020-11-25
- Last updated
- 2023-08-07
- Results posted
- 2023-08-07
Locations
29 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04644315. Inclusion in this directory is not an endorsement.